secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001628280-26-011987
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Rhythm Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results; IMCIVREE Revenue $57.3M in Q4
--------------------------------------------------------------------------------

- Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.
- FDA PDUFA date March 20, 2026 for setmelanotide in acquired hypothalamic obesity.
- Positive end-of-Phase-2 meeting with FDA for bivamelagon in acquired HO; Phase 3 trial to start by end of 2026.
- Cash and investments $388.9M at Dec 31, 2025; net loss $48.8M in Q4 2025 vs $44.6M in Q4 2024.
- Topline data expected March 2026 from Phase 3 EMANATE trial and Japanese cohort in acquired HO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/0001628280-26-011987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-011987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer